Roche CFO says comfortable with consensus giredestrant sales forecasts ahead of December launch

Roche CFO Alan Hippe said the company is comfortable with consensus sales forecasts for giredestrant, its breast cancer treatment expected to launch in December, projecting 2027 sales of CHF 500-600 million. Roche plans a 6-9 month bridge program to ensure immediate patient access.

Detected & updated continuously · Source: Nebula